Journal
EMBO MOLECULAR MEDICINE
Volume 10, Issue 4, Pages -Publisher
WILEY
DOI: 10.15252/emmm.201707918
Keywords
collagen receptor; colorectal cancer; invasion; targeted therapy; tyrosine kinase
Categories
Funding
- ARC
- Montpellier SIRIC Grant [INCa-DGOS-Inserm 6045]
- Ligue Nationale contre le Cancer
- CNRS
- University of Montpellier
- Montpellier SIRIC
- Fondation pour la Recherche Medicale
- INSERM
- Fondation de France
Ask authors/readers for more resources
The clinical management of metastatic colorectal cancer (mCRC) faces major challenges. Here, we show that nilotinib, a clinically approved drug for chronic myeloid leukaemia, strongly inhibits human CRC cell invasion invitro and reduces their metastatic potential in intrasplenic tumour mouse models. Nilotinib acts by inhibiting the kinase activity of DDR1, a receptor tyrosine kinase for collagens, which we identified as a RAS-independent inducer of CRC metastasis. Using quantitative phosphoproteomics, we identified BCR as a new DDR1 substrate and demonstrated that nilotinib prevents DDR1-mediated BCR phosphorylation on Tyr177, which is important for maintaining -catenin transcriptional activity necessary for tumour cell invasion. DDR1 kinase inhibition also reduced the invasion of patient-derived metastatic and circulating CRC cell lines. Collectively, our results indicate that the targeting DDR1 kinase activity with nilotinib may be beneficial for patients with mCRC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available